metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Mexican experience with direct-acting antivirals in the treatment of hepatitis C
Información de la revista
Vol. 19. Núm. S1.
Abstracts of the 2020 Annual meeting of the Mexican Association of Hepatology (AMH) – XV Congreso Nacional de Hepatología (23-25 de julio)
Páginas 16 (septiembre 2020)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 19. Núm. S1.
Abstracts of the 2020 Annual meeting of the Mexican Association of Hepatology (AMH) – XV Congreso Nacional de Hepatología (23-25 de julio)
Páginas 16 (septiembre 2020)
33
Open Access
Mexican experience with direct-acting antivirals in the treatment of hepatitis C
Visitas
708
J.L. Pérez Hernández, C.A. Arce Salinas, R. Lehmman Mendoza, A. Torre Delgadillo, G. Castro Narro, E. Cerda Reyes, M.V. Ramos Gómez, L. Juárez Chávez, M. Dehesa Violante, L. Muñoz Espinosa, L. Cisneros Garza, I. Aiza Haddad, J.A. Velarde Ruiz Velasco, R. Contreras Omaña, N. García Casarreal, J.A. Carmona Castañeda, M.F. Higuera de la Tijera
Hospital General de México “Dr. Eduardo Liceaga” Ciudad de México, México
Este artículo ha recibido

Under a Creative Commons license
Información del artículo
Texto completo
Descargar PDF
Estadísticas
Figuras (1)
Texto completo

Background and aim: Chronic hepatitis C infection, develops cirrhosis with all its complications, the arrival in our country of direct-acting antivirals (DAAs), gave the opportunity to have safer and more effective drugs.

Material and methods: Retrospective, cross-sectional study of patients who received AAD in hospitals in the Mexican Republic. 20 hospital centers. Variables analyzed: gender, age, genotype, degree of fibrosis, initial and final viral load of ADA treatment. SVR and side effects were documented. Descriptive statistics were performed.

Results: Were included 813 patients, 529 women and 284 men, age 58.88±12.10 years were included. Genotype 1: 647 patients (1A: 316, 1B: 318, 1A / B: 11 and 1 A / C: 2), genotype 2: 145, genotype 3:19 and genotype 4: 2. By degree of fibrosis: F0: 93 F1: 88, F2; 86, F3: 95 and F4; 451. Patients with F4 (451), Child Pugh were classified as A: 363 and B: 88. From the Child Pugh group A 7 (1.9%) did not respond and from the group B 1 (1.1%). There were 561 näive and 252 no näive, the percentage that presented SVR was from 90 to 100%. The most frequent side effects: headache 16% and fatigue 22%, nausea (3%), muscle pain (1%), abdominal pain (1%), with ribavirin, anemia was documented in 22%.

Conclusions: Direct Action Antivirals is an effective and safe option in the Mexican population studied. Adverse events were not significant.

Conflicts of interest: The authors have no conflicts of interest to declare.

Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2020.08.035
No mostrar más